

Independent Auditor's Review Report on Standalone unaudited financial results of Wockhardt Limited for the quarter and year to date ended September 30, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Wockhardt Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Wockhardt Limited (hereinafter referred to as 'the Company') for the quarter ended September 30, 2024 and the year to-date results for the period from April 01, 2024 to September 30, 2024 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



MSKC & Associates

Chartered Accountants

5. The Statement of the Company for the quarter and six months ended September 30, 2023 and for the year ended March 31, 2024 was reviewed/audited by the predecessor auditor whose report dated November 14, 2023 and May 28, 2024 respectively, expressed an unmodified conclusion/opinion on that Statement.

Our conclusion is not modified in respect of the above matter.

For M S K C & Associates

Chartered Accountants

ICAI Firm Registration Number: 0015955



Bhavik L. Shah

Membership No.: 122071

UDIN: 24122071BKENEW8858



Place: Mumbai

Date: November 13, 2024

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhaji Nagar - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051
CIN:L24230MH1999PLC120720

Tel: 91 22 2653 4444 ; Fax: 91 22 2652 3905; e-mail id : investorrelations@wockhardt.com; Website: www.wockhardt.com

(Rs in Crore except per share data)						
STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2024						
PARTICULARS	3 MONTHS ENDED 30/09/2024	3 MONTHS ENDED 30/06/2024	3 MONTHS ENDED 30/09/2023	6 MONTHS ENDED 30/09/2024	6 MONTHS ENDED 30/09/2023	YEAR ENDED 31/03/2024
(Refer notes below)	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income						
(a) Revenue from operations	370	352	260	722	511	1,154
(b) Other income	11	27	6	37	12	41
Total income	381	379	266	759	523	1,195
2 Expenses						
(a) Cost of materials consumed	88	82	51	170	113	285
(b) Purchase of stock-in-trade	51	31	41	82	76	162
(c) Changes in inventories of finished goods, work in progress and stock-in-trade	(1)	14	13	13	19	14
(d) Employee benefits expense	65	62	63	127	126	247
(e) Finance costs	53	58	59	111	117	237
(f) Depreciation and amortisation expense	43	43	44	86	88	176
(g) Impairment of asset held for sale	-	-	-	-	-	79
(h) Exchange fluctuation loss, net	-	1	-	-	-	-
(i) Other expenses	118	82	102	200	192	403
Total expenses	417	373	373	789	731	1,603
3 (Loss)/Profit before exceptional items and tax (1-2)	(36)	6	(107)	(30)	(208)	(408)
4 Exceptional items- charge	-	-	-	-	(14)	(14)
5 (Loss)/Profit after exceptional items before tax (3 + 4)	(36)	6	(107)	(30)	(222)	(422)
6 Tax expense:						
Current tax	-	-	-	-	-	-
Deferred tax	-	-	-	-	-	-
7 Net (Loss)/Profit after tax (5 ± 6)	(36)	6	(107)	(30)	(222)	(427)
8 Other Comprehensive Income:						
i) Items that will not be reclassified to Profit or Loss - (charge)/credit (consisting of re-measurement of net defined benefit (liability)/asset)	(0.26)	(0.26)	0.44	(1)	1	(1)
ii) Income tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
iii) Other Comprehensive Income (net of tax) (8i ± 8ii)	(0.26)	(0.26)	0.44	(1)	1	(1)
9 Total Comprehensive Income (7 ± 8(iii))	(36)	6	(107)	(31)	(221)	(425)
10 Paid-up equity share capital (face value of Rs. 5/- each)	77	77	72	77	72	77
11 Other Equity excluding Revaluation Reserves as per balance sheet						1,719
12 Earnings per share (face value of Rs. 5/- each) (*not annualised)						
(a) Basic (Rs.)	(2.34)*	0.39*	(7.39)*	(1.96)*	(15.40)*	(29.27)
(b) Diluted (Rs.)	(2.34)*	0.39*	(7.39)*	(1.96)*	(15.40)*	(29.27)



[Handwritten Signature]




Notes To Standalone Results :-

- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 13, 2024. The results have been subjected to limited review by the Statutory Auditors of the Company.
- 2) During the quarter ended September 30, 2024, the Company has allotted 8,610 (Year to date: 8,610) Equity shares of face value of Rs. 5/- each pursuant to exercise of employee stock options.
- 3) Further to the approval of the Board of Directors and Shareholders at their meetings, the Company has, on November 11, 2024, allotted 9,049,773 Equity Shares of Rs. 5/- each to successful Qualified Institutional Buyers at the issue price of Rs. 1,105/- per share, aggregating to approximately Rs. 1,000 crore.
- 4) The Company is exclusively into Pharmaceutical business segment.

Mumbai
Date: November 13, 2024

FOR WOCKHARDT LIMITED



H.F. KHORAKIWALA
CHAIRMAN
DIN:00045608



STATEMENT OF STANDALONE ASSETS AND LIABILITIES

(Rs. in Crore)

PARTICULARS		As at 30/09/2024 Unaudited	As at 31/03/2024 Audited
A)	ASSETS		
1	Non- Current assets		
	(a) Property, plant and equipment	1,029	1,079
	(b) Right of use assets	283	315
	(c) Capital work-in-progress	69	56
	(d) Intangible assets	45	55
	(e) Intangible assets under development	956	777
	(f) Financial assets		
	(i) Investments in subsidiaries	297	297
	(ii) Other Investments *	0	0
	* Rs. 0.45 crore (Previous year - Rs. 0.45 crore)		
	(iii) Other non-current financial assets	65	64
	(g) Non-current tax assets (Net)	75	99
	(h) Deferred tax assets (Net)	250	250
	(i) Other non-current assets	104	97
	Sub-total- Non-current assets	3,173	3,089
2	Current assets		
	(a) Inventories	318	321
	(b) Financial assets		
	(i) Investments	48	-
	(ii) Trade receivables	707	566
	(iii) Cash and cash equivalents	50	463
	(iv) Bank balances (other than Cash and cash equivalents)	29	23
	(v) Other current financial assets	98	101
	(c) Other current assets	214	194
	Sub-total - Current assets	1,464	1,668
3	Assets classified as held for sale	104	111
	TOTAL ASSETS	4,741	4,868
B)	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity share capital	77	77
	(b) Other Equity	1,688	1,719
	Sub-total- Equity	1,765	1,796
2	Liabilities		
I.	Non- Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	925	891
	(ii) Lease Liabilities	221	265
	(b) Provisions	30	28
	Sub-total- Non-current liabilities	1,176	1,184
II.	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	847	899
	(ii) Lease Liabilities	73	81
	(iii) Trade payables		
	a. Total outstanding dues of Micro enterprises and Small enterprises	25	28
	b. Total outstanding dues of creditors other than micro enterprises and small enterprises	508	552
	(iv) Other current financial liabilities	205	173
	(b) Other current liabilities	113	127
	(c) Provisions	27	26
	(d) Current tax liabilities (Net)	2	2
	Sub-total- Current liabilities	1,800	1,888
	Total Liabilities	2,976	3,072
	TOTAL EQUITY AND LIABILITIES	4,741	4,868

FOR WOCKHARDT LIMITED

H F KHORAKIWALA
CHAIRMAN
DIN: 00045608

Mumbai
Date: November 13, 2024



WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhaji Nagar - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

STANDALONE UNAUDITED CASH FLOW STATEMENT FOR SIX MONTHS ENDED SEPTEMBER 30, 2024

PARTICULARS	(Rs. in Crore)	
	6 MONTHS ENDED 30/09/2024	6 MONTHS ENDED 30/09/2023
(Refer notes below)	Unaudited	Unaudited
Cash flow from/(used in) Operating activities		
Loss before tax	(30)	(222)
Adjustments for:		
Exceptional items- Provision against inventories	-	14
Depreciation and amortisation expense	86	88
(Reversal of)/Allowance for expected credit loss, doubtful advances and bad debts	(11)	1
Loss/(Profit) on sale of fixed assets (Net)*	0	0
[*Rs. 0.36 crore (Previous period- Rs. 0.09 crore)]		
Gain on sale of investments	(4)	-
Finance costs	111	117
Net foreign exchange fluctuation (gain)/loss, net	(6)	23
Interest income	(5)	(3)
Employee share based payments expenses*	0	1
[*current period Rs. 0.33 crore]		
Liabilities no longer required written back	(23)	(1)
Fair valuation impact on investments	(1)	-
	117	18
Movements in Working capital		
Decrease in Inventories	3	22
(Increase)/Decrease in Trade receivables	(130)	49
(Increase)/Decrease in Loans and Advances and other assets	(32)	31
(Decrease)/Increase in Liabilities and provisions	(10)	7
Decrease in Trade payables	(48)	(40)
Cash (used in)/from operations	(100)	87
Income tax Refund (net)	27	-
Net cash (outflow) /inflow from Operating activities	(73)	87
Cash flow from/(used in) Investing activities		
Purchase of property, plant and equipment and capital work-in progress	(24)	(4)
Proceeds from sale of Property, Plant and Equipment (including asset held for sale)*	7	0
[*Previous period- Rs. 0.01 crore]		
Guarantee commission received	24	-
Purchase of Intangible assets and Intangible assets under development	(144)	(30)
Purchase of current investments	(364)	-
Sale of current investments	321	-
Margin money under lien and Bank balances (other than cash and cash equivalents)	(6)	5
Interest received*	0	1
[*current period Rs. 0.33 crore]		
Net cash outflow from Investing activities	(186)	(28)
Cash flow from/(used in) Financing activities		
Transaction cost related to Right Issue/ Qualified Institutional Placement (QIP)	(2)	(1)
Proceeds from Issuance of Equity share capital under ESOS*	0	0
[* Rs. 0.004 crore (Previous period- Rs. 0.003 crore)]		
Repayment of Long-term borrowings	(97)	(101)
Short-term borrowings (net)	3	(23)
Loans from Related parties- Long term	47	222
Repayment of loans taken from Related parties- Long term	(4)	(47)
Repayment of loans taken from Related parties- Short term	(13)	(11)
Repayment of Lease liabilities (refer note 2 below)	(38)	(41)
Finance costs paid	(50)	(57)
Net cash outflow from Financing activities	(154)	(59)
Net Decrease in Cash and Cash equivalents	(413)	-
Cash and cash equivalents as at the beginning of the year	463	4
Cash and cash equivalents as at the end of the period	50	4



[Handwritten signature]



Reconciliation of cash and cash equivalents as per the cash flow statement:

(Rs. in Crore)

	As at 30/09/2024	As at 30/09/2023
Cash and cash equivalents as per above comprise of the following:		
Cash	-	-
Balance with banks:		
- in current account	50	4
Balance as per the Statement of cash flows	50	4

Notes:

- The above statement of cash flows has been prepared under the indirect method as set out in Ind AS 7 'Statement of Cash Flows'.
- Repayment of lease liabilities consists of:
 Payment of interest Rs. 14 crore (Previous period - Rs. 18 crore)
 Payment of Principal Rs. 24 crore (Previous period - Rs. 23 crore)
- Figures in bracket indicate cash outflow.

FOR WOCKHARDT LIMITED

Mumbai
 Date: November 13, 2024

H F KHORAKIWALA
 H F KHORAKIWALA
 CHAIRMAN
 DIN: 00045608



Independent Auditor's Review Report on Consolidated unaudited financial results of Wockhardt Limited for the quarter ended and year to date September 30, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Wockhardt Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Wockhardt Limited (hereinafter referred to as 'the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended September 30, 2024 and the year to-date results for the period from April 01, 2024 to September 30, 2024 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Wockhardt UK Holdings Limited	Wholly Owned Subsidiary
2	CP Pharmaceuticals Limited	Step-Down Subsidiary
3	CP Pharma (Schweiz) AG	Step-Down Subsidiary
4	Wallis Group Limited	Step-Down Subsidiary



MSKC & Associates

Chartered Accountants

5	The Wallis Laboratory Limited	Step-Down Subsidiary
6	Wockhardt Farmaceutica Do Brasil Ltda	Step-Down Subsidiary
7	Wallis Licensing Limited	Step-Down Subsidiary
8	Wockhardt Infrastructure Development Limited	Wholly Owned Subsidiary
9	Z&Z Services GmbH	Step-Down Subsidiary
10	Wockhardt Europe Limited	Wholly Owned Subsidiary
11	Wockhardt Nigeria Limited	Step-Down Subsidiary
12	Wockhardt USA LLC	Step-Down Subsidiary
13	Wockhardt UK Limited	Step-Down Subsidiary
14	Wockpharma Ireland Limited	Step-Down Subsidiary
15	Pinewood Laboratories Limited	Step-Down Subsidiary
16	Pinewood Healthcare Limited	Step-Down Subsidiary
17	Wockhardt France (Holdings) S.A.S.	Step-Down Subsidiary
18	Wockhardt Holding Corp.	Step-Down Subsidiary
19	Morton Grove Pharmaceuticals Inc.	Step-Down Subsidiary
20	MGP Inc.	Step-Down Subsidiary
21	Wockhardt Farmaceutica SA DE CV	Step-Down Subsidiary
22	Wockhardt Services SA DE CV	Step-Down Subsidiary
23	Wockhardt Bio AG	Subsidiary
24	Wockhardt Bio (R) LLC	Step-Down Subsidiary
25	Wockhardt Bio Pty Limited	Step-Down Subsidiary
26	Wockhardt Bio Limited	Step-Down Subsidiary
27	Wockhardt Medicines Limited	Wholly Owned Subsidiary
28	Wockhardt Bionova Limited (formerly known as Wockhardt Biologics Limited until April 22, 2024)	Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required



MSKC & Associates

Chartered Accountants

to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of 5 subsidiaries included in the Statement, whose interim financial information (before Consolidation Adjustments) reflects total assets of Rs. 6,999 crores as at September 30, 2024 and total revenues of Rs. 807 crores and Rs.1,465 crores, total net profit after tax of Rs. 44 crores and Rs. 22 crores and total comprehensive income of Rs. 44 crores and Rs. 22 crores, for the quarter ended September 30, 2024 and for the period from April 01, 2024 to September 30, 2024 respectively and cash flows (net) of Rs. 59 crores for the period from April 01, 2024 to September 30, 2024 as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditors.

7. The Statement includes the interim financial information of 18 subsidiaries which have not been reviewed by their auditors, whose interim financial information (before Consolidation Adjustments) reflects total assets of Rs. 197 crores as at September 30, 2024 and total revenue of Rs. 20 crores and Rs.36 crores, total net profit after tax of Rs. 1 crore and Rs. 6 crores and total comprehensive income of Rs. 1 crore and Rs. 6 crores for the quarter ended September 30, 2024 and for the period from April 01, 2024 to September 30, 2024 respectively and cash outflows (net) of Rs. 6 crores for the period from April 01, 2024 to September 30, 2024 as considered in the Statement. These interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial result certified by the management.

8. The Statement of the Group for the quarter and six months ended September 30, 2023 and for the year ended March 31, 2024 was reviewed/audited by the predecessor auditor whose report dated November 14, 2023 and May 28, 2024 respectively, expressed an unmodified conclusion/opinion on that Statement.

Our conclusion is not modified in respect of the above matter.

For M S K C & Associates

Chartered Accountants

ICAI Firm Registration Number: 0015955



Bhavik L. Shah

Membership No.: 122071

UDIN: 24122071BKENEX6786



Place: Mumbai

Date: November 13, 2024

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhaji Nagar - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051
CIN: L24230MH1999PLC120720
Tel: 91 22 2653 4444; Fax: 91 22 2652 3905; e-mail id: investorrelations@wockhardt.com, Website: www.wockhardt.com

(Rs. in Crore except per share data)							
STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2024							
	PARTICULARS	3 MONTHS ENDED 30/09/2024	3 MONTHS ENDED 30/06/2024	3 MONTHS ENDED 30/09/2023	6 MONTHS ENDED 30/09/2024	6 MONTHS ENDED 30/09/2023	YEAR ENDED 31/03/2024
	(Refer Notes Below)	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
1	(a) Revenue from operations	809	739	753	1,548	1,397	2,798
	(b) Other income	9	30	24	39	36	83
	Total income	818	769	777	1,587	1,433	2,881
	Expenses						
	(a) Cost of materials consumed	182	150	179	332	316	620
	(b) Purchase of stock-in-trade	150	153	105	303	255	559
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(35)	10	3	(25)	(2)	(14)
2	(d) Employee benefits expense	161	160	166	321	320	629
	(e) Finance costs	73	73	76	146	155	305
	(f) Depreciation and amortisation expense	55	54	55	109	110	223
	(g) Impairment of asset held for sale	-	-	-	-	-	79
	(h) Exchange fluctuation loss, net	20	1	-	21	-	-
	(i) Loss on sale of property, plant and equipment	-	-	-	-	-	52
	(j) Other expenses	221	174	228	395	418	844
	Total expenses	827	775	812	1,602	1,572	3,287
3	Profit/(Loss) before exceptional items and tax (1-2)	(9)	(6)	(35)	(15)	(139)	(406)
4	Exceptional items- charge	-	-	-	-	(14)	(14)
5	Profit/(Loss) after exceptional items and before tax (3 ± 4)	(9)	(6)	(35)	(15)	(153)	(420)
	Tax expense:						
6	Current tax - charge	3	2	2	5	11	16
	Deferred tax - charge/(credit) - (Net)	4	8	36	12	45	36
7	Profit/(Loss) after tax (5 ± 6)	(16)	(16)	(73)	(32)	(209)	(472)
	Attributable to:						
	Equity shareholders of the Company	(22)	(14)	(77)	(36)	(211)	(463)
	Non - Controlling Interest	6	(2)	4	4	2	(9)
8	Other Comprehensive Income						
	(a) Items that will not be reclassified to Profit or Loss - (charge)/ credit (consisting of re-measurement of net defined benefit (liability) / asset)	(0.26)	(0.26)	0.44	(1)	1	(9)
	(b) Income tax relating to items that will not be reclassified to Profit or Loss - credit/(charge)	-	-	-	-	-	1
	(c) Items that will be reclassified to Profit or Loss - (charge)/ credit (Consisting of Exchange differences on translating the financial statements of foreign operations)	89	(3)	(20)	86	(22)	14
	(d) Other Comprehensive Income (net of tax) (a + b + c)	89	(3)	(20)	85	(21)	6
9	Total Comprehensive Income (7 ± 8 (d))	73	(19)	(93)	53	(230)	(466)
	Total Comprehensive Income attributable to:						
	Equity shareholders of the Company	59	(18)	(95)	40	(229)	(461)
	Non - Controlling Interest	14	(1)	2	13	(1)	(5)
10	Paid-up equity share capital (face value of Rs. 3/- each)	77	77	72	77	72	77
11	Other Equity excluding Revaluation Reserves as per Balance Sheet						3,282
12	Earnings per equity share (face value of Rs. 5/- each) (*not annualised)						
	(a) Basic (Rs.)	(1.47)*	(0.95)*	(5.37)*	(2.42)*	(14.65)*	(32.05)*
	(b) Diluted (Rs.)	(1.47)*	(0.95)*	(5.37)*	(2.42)*	(14.65)*	(32.05)*



Notes To Consolidated Results:-

- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 13, 2024. The results have been subjected to limited review by the Statutory Auditors of the Company.
- 2) The Consolidated Results relate to Wockhardt Limited ('the Company' or 'the Holding Company') and its Subsidiaries (together constitute 'the Group') and are prepared by applying Ind AS 110 - "Consolidated Financial Statements".
- 3) **Key Financials on Standalone basis:**


PARTICULARS	3 MONTHS ENDED 30/09/2024	3 MONTHS ENDED 30/06/2024	3 MONTHS ENDED 30/09/2023	6 MONTHS ENDED 30/09/2024	6 MONTHS ENDED 30/09/2023	YEAR ENDED 31/03/2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total Income	381	379	266	759	523	1,195
Profit (Loss) before tax	(36)	6	(107)	(30)	(222)	(422)
Profit (Loss) after tax	(36)	6	(107)	(30)	(222)	(422)

Note: The unaudited standalone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2013 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com) and also on the Company's website www.wockhardt.com.

- 4) Further to the approval of the Board of Directors and Shareholders at their meetings, the Company has, on November 11, 2024, allotted 9,049,773 Equity Shares of Rs. 5/- each to successful Qualified Institutional Buyers at the issue price of Rs. 1.105/- per share, aggregating to approximately Rs. 1,000 crore.
- 5) During the quarter ended September 30, 2024, the Company has allotted 8,610 (Year to date: 8,610) Equity shares of face value of Rs. 5/- each pursuant to exercise of employee stock options.
- 6) The Group is exclusively into Pharmaceutical business segment.
- 7) For List of Subsidiaries as on September 30, 2024 please refer Annexure.

Mumbai
Date : November 13, 2024

FOR WOCKHARDT LIMITED



H F KHORAKIWALA
CHAIRMAN
DIN: 00045608



STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES

		(Rs. in Crore)	
	PARTICULARS	As at 30/09/2024	As at 31/03/2024
		Unaudited	Audited
A)	ASSETS		
1	Non- Current assets		
	(a) Property, Plant and Equipment	1,432	1,467
	(b) Right of use assets	374	408
	(c) Capital work-in-progress	481	434
	(d) Goodwill	991	953
	(e) Other Intangible assets	50	53
	(f) Intangible assets under development	1,407	1,288
	(g) Financial assets		
	(i) Investments	-	-
	Rs. 0.45 crore (Previous year - Rs. 0.45 crore)		
	(ii) Other non- current Financial assets	66	65
	(h) Non-current tax assets (Net)	79	117
	(i) Deferred tax assets (Net)	588	579
	(j) Other non-current assets	112	101
	Sub-total - Non-current assets	5,580	5,465
2	Current assets		
	(a) Inventories	657	640
	(b) Financial assets		
	(i) Investments	48	
	(ii) Trade receivables	695	618
	(iii) Cash and cash equivalents	143	505
	(iv) Bank balance (other than Cash and cash equivalents)	32	24
	(v) Other current Financial assets	35	18
	(c) Other current assets	294	268
	Sub-total - Current assets	1,904	2,073
3	Asset classified as held for sale	104	111
	TOTAL ASSETS	7,588	7,649
B)	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity share capital	77	77
	(b) Other Equity	3,318	3,282
	Equity attributable to the share holders of the Company	3,395	3,359
	(c) Non - Controlling Interest	318	303
	Sub-total- Equity	3,713	3,662
2	Liabilities		
I.	Non- Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	1,219	891
	(ii) Lease Liabilities	123	170
	(b) Other non-current liabilities	70	72
	(c) Provisions	30	28
	(d) Deferred tax liabilities (Net)	53	35
	Sub-total- Non-current liabilities	1,495	1,196
II.	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	935	1,221
	(ii) Lease Liabilities	66	74
	(iii) Trade payables	677	766
	(iv) Other current financial liabilities	498	518
	(b) Other current liabilities	145	163
	(c) Provisions	49	39
	(d) Current tax liabilities (Net)	10	10
	Sub-total- Current liabilities	2,380	2,791
	Total Liabilities	3,875	3,987
	TOTAL EQUITY AND LIABILITIES	7,588	7,649

FOR WOCKHARDT LIMITED

H F KHORAKI WALA
CHAIRMAN
DIN: 00045608

Mumbai
Date : November 13, 2024



CONSOLIDATED UNAUDITED CASH FLOW STATEMENT FOR SIX MONTHS ENDED SEPTEMBER 30, 2024

		(Rs in crore)	
	PARTICULARS	6 MONTHS ENDED 30/09/2024	6 MONTHS ENDED 30/09/2023
	(Refer notes below)	Unaudited	Unaudited
A	CASH FLOWS FROM / (USED IN) OPERATING ACTIVITIES:		
	Loss after exceptional items and before tax	(15)	(153)
	Adjustments for :		
	Exceptional items - Provision against inventories/ contract assets	-	14
	Depreciation and amortization expense	109	110
	Allowance/(Reversal of allowance) for expected credit loss, doubtful advance and Bad debts provision	(12)	18
	(Profit)/ Loss on assets sold/ write off of fixed assets (net)*	0	0
	*[Rs. 0.36 crore (Previous period- Rs. 0.09 crore)]		
	Finance costs	146	155
	Foreign exchange loss/ (gain), net	-	(13)
	Interest income	(6)	(2)
	Employee share based payments expenses*	0	1
	*[Rs 0.33 Cr for current year]		
	Liabilities no longer required written back	(22)	(1)
	Movements In Working capital	200	129
	Decrease in Inventories	4	12
	(Increase) /Decrease in trade receivables	(60)	67
	(Increase) / Decrease in Loans and Advances and other assets	(53)	35
	(Decrease) in Liabilities and provisions	(95)	(121)
	Cash generated from operations	(4)	122
	Income tax refund / (paid)	36	(18)
	Net cash inflow from Operating activities (A)	32	104
B	CASH FLOWS FROM / (USED IN) INVESTING ACTIVITIES:		
	Purchase of Property, Plant and Equipment and Capital work-in progress	(48)	(12)
	Purchase of Intangible assets and Addition in Intangible assets under development	(155)	(82)
	Proceeds from sale of property, plant and equipment (including asset held for sale)*	7	0
	*[Previous period- Rs. 0.01 crore]		
	Margin money under lien and Bank balances (other than cash and cash equivalents)	(8)	5
	Purchases of current investments	(364)	-
	Sale of current investments	317	-
	Interest received	4	1
	Net cash (outflow) Investing activities (B)	(247)	(88)
C	CASH FLOWS FROM / (USED IN) FINANCING ACTIVITIES		
	Transaction cost related to Right Issue/ Qualified Institutional Placement (QIP)	(2)	(1)
	Proceeds from Issuance of Equity share capital under ESOS*	0	0
	*[Rs. 0,004 crore (Previous period- Rs. 0,003)]		
	Proceeds of term loan	299	-
	Repayment of long-term borrowings	(327)	(121)
	Short-term borrowings (net)	(24)	35
	Loans from related parties	47	222
	Repayment of loans taken from related parties- Long term	(4)	(47)
	Repayment of loans taken from related parties- Short term	(13)	(11)
	Repayment of Lease liabilities (Refer note 2 below)	(35)	(38)
	Finance costs paid	(88)	(89)
	Equity Dividend paid to IEPF*	-	(0)
	*[Previous year- Rs. 0.49 crore]		
	Net cash inflow/ (outflow) from Financing activities (C)	(147)	(50)
	NET (DECREASE)/ INCREASE IN CASH AND CASH EQUIVALENTS (A+B+C)	(362)	(34)
	Cash and cash equivalents as at the beginning of the year	505	90
	Exchange difference on translation of foreign cash and cash equivalent	-	(2)
	Cash and cash equivalents as at the end of the period	143	54
	Reconciliation of cash and cash equivalents as per the cash flow statement		
	Cash and cash equivalents as per above comprise of the following		
	Balance with banks:		
	- in current accounts	143	54
		143	54

Notes:

- The above statement of cash flows has been prepared under the indirect method as set out in Ind AS 7 'Statement of Cash Flows'.
- Repayment of lease liabilities consists of:
Payment of Interest ₹ 9 crore (Previous year: ₹ 14 crore)
Payment of Principal ₹ 26 crore (Previous year: ₹ 21 crore)
- Figures in bracket indicate cash outflow.

Mumbai
Date : November 13, 2024

FOR WOCKHARDT LIMITED

H F KHORAKI WALA
CHAIRMAN
DIN: 00045608



WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhaji Nagar - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

Annexure to Note 7 of Consolidated unaudited Results for the Quarter and six months ended September 30, 2024.

List of Subsidiaries as on September 30, 2024

- 1 Wockhardt UK Holdings Limited
- 2 CP Pharmaceuticals Limited
- 3 CP Pharma (Schweiz) AG
- 4 Wallis Group Limited
- 5 The Wallis Laboratory Limited
- 6 Wockhardt Farmaceutica Do Brasil Ltda
- 7 Wallis Licensing Limited
- 8 Wockhardt Infrastructure Development Limited
- 9 Z & Z Services GmbH
- 10 Wockhardt Europe Limited
- 11 Wockhardt Nigeria Limited
- 12 Wockhardt USA LLC
- 13 Wockhardt UK Limited
- 14 Wockpharma Ireland Limited
- 15 Pinewood Laboratories Limited
- 16 Pinewood Healthcare Limited
- 17 Wockhardt France (Holdings) S.A.S.
- 18 Wockhardt Holding Corp.
- 19 Morton Grove Pharmaceuticals Inc.
- 20 MGP Inc.
- 21 Wockhardt Farmaceutica SA DE CV
- 22 Wockhardt Services SA DE CV
- 23 Wockhardt Bio AG
- 24 Wockhardt Bio (R) LLC
- 25 Wockhardt Bio Pty Limited
- 26 Wockhardt Bio Limited
- 27 Wockhardt Medicines Limited
- 28 Wockhardt Bionova Limited (formerly known as Wockhardt Biologics Limited until April 22, 2024)



[Handwritten signature]

